Earnings Per Share

3 Months Ended

Dec. 31, 2023

Earnings Per Share [Abstract]

Earnings Per Share

EARNINGS PER SHARE

The following table presents the computation of basic and diluted earnings per share for the three months ended December 31, 2023 and 2022.

	Three Months Ended December 31,
	2023		2022
	(in thousands, except per share amounts)
Numerator:
Net loss attributable to Arrowhead Pharmaceuticals, Inc.	$	(132,864)	$	(41,325)
Denominator:
Weighted-average basic shares outstanding	107,415		106,039
Effect of dilutive securities	—		—
Weighted-average diluted shares outstanding	107,415		106,039
Basic earnings per share	$	(1.24)	$	(0.39)
Diluted earnings per share	$	(1.24)	$	(0.39)

Potentially dilutive securities representing approximately 3,544,000 and 3,327,000 shares of common stock were excluded from the computation of diluted earnings per share for the three months ended December 31, 2023 and 2022, respectively, because their effect would have been anti-dilutive.